Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Placenta polypeptide injection is a biologic therapeutic derived from human placental tissue, containing a complex mixture of low-molecular-weight peptides, amino acids, and nucleic acid components. It is widely utilized in China as an immunomodulator and anti-inflammatory agent. The drug is indicated for the adjunctive treatment of various conditions, including immune deficiencies, chronic inflammatory diseases, and as a supportive therapy for cancer patients to mitigate the side effects of chemotherapy and radiotherapy. In the context of dermatology, it is being investigated for its ability to treat moderate to severe sensitive skin by inhibiting inflammatory responses and promoting skin barrier repair, as evidenced by clinical trials conducted at institutions like Peking Union Medical College Hospital.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placenta polypeptide injection.